Fosun is the largest listing in Hong Kong since Inner Mongolia Yitai Coal’s $900m deal in July. The $1.8bn listing in April of Haitong Securities, China’s second-biggest broker by assets, was the only other significant deal this year.
复星医药上市,是自内蒙古伊泰煤矿(Inner Mongolia Yitai Coal)今年7月在港融资9亿美元以来,香港最大规模的IPO。除这两家公司以外,今年香港的大型IPO只有4月份融资18亿美元的海通证券(Haitong Securities)。按资产规模计算,海通证券是中国第二大证券公司。
Fosun’s IPO was priced at HK$11.80 per share, amounting to a 9.9 per cent discount to the 20-day average of its Shanghai stock price. Beijing prohibits Chinese companies from pricing Hong Kong deals at more than a 10 per cent discount.
复星医药IPO每股定价11.80港元,与其A股最近20个交易日平均股价相比折让9.9%。中国政府规定,中国内地公司在香港IPO定价的折让上限为10%。
The shares fell as low as HK$10.38 in early trading on Tuesday before recovering to close at HK$10.84, still 8 per cent below their listing price.
复星医药股价周二早盘最低跌至10.38港元,收盘反弹至10.84港元,但仍较招股价下跌8%。
The listing, which was run by China International Capital Corp, Deutsche Bank, JPMorgan, UBS, Agricultural Bank of Chinaand Haitong Securities, initially looked promising. The company sold a roughly 15 per cent stake to two cornerstone investors, who pledge money ahead of the formal listing process. Prudential Financialof the US pledged $50m and the IFC, the financing arm of the World Bank, pledged $25m.
【复星医药香港交易首日表现堪忧】相关文章:
★ 狼与鹤
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15